- Policy
- Series of expectorant Prospan generics enter KOR mkt
- by Lee, Tak-Sun Dec 22, 2023 05:46am
- Generic versions of Prospan Syrup, a drug that dominated the phyto-expectorant market in the 2000s, are again being introduced to the market. Prospan Syrup, which has been resold by Kwangdong Pharmaceutical since 2012, is the only available 200mL bottle formulation of Prospan, and 7.5mL and bottle formulations of the drug are only availa
- Policy
- Delayed re-evaluation of hyaluronic acid eye drops
- by Lee, Tak-Sun Dec 21, 2023 05:54am
- The re-evaluation of the reimbursement appropriateness of hyaluronic acid (HA) eye drops has ultimately been delayed. On the 7th, the Health Insurance Review and Assessment Service (HIRA)’s Drug Reimbursement Committee decided to conduct an additional review of the re-evaluation item. Similarly, on the 20th, the Ministry of Health and W
- Policy
- Braftovi Cap. & Bosulif tablets reimb for the New Year
- by Lee, Tak-Sun Dec 21, 2023 05:39am
- Starting on Jan 1 next month, two anti-cancer drugs will be reimbursed. These drugs include Ono Pharmaceutical Korea’s Braftovi Cap. 75mg (encorafenib) and the 3 Pfizer Korea’s Bosulif tablet tiems. Braftovi has been listed following drug price negotiation with the National Health Insurance Service, and Bosulif was not subject to maximum
- Company
- 30 companies do not fulfill disability employment obligation
- by Kim, Jin-Gu Dec 21, 2023 05:39am
- Twenty-nine Korean pharmaceutical and biotech companies have failed to fulfill their obligations to hire people with disabilities. The Ministry of Employment and Labor added AstraZeneca Korea to the list for 10 consecutive years and Kolon Pharmaceutical for 3 consecutive years due to their failure in fulfilling their disability hiring obli
- Company
- ‘Use of Cosentyx will rise in ankylosing spondylitis’
- by Son, Hyung-Min Dec 21, 2023 05:39am
- Reimbursement for Novartis' Cosentyx has been expanded to the first-line in ankylosing spondylitis in Korea. The rise of the new reimbursed drug option in the treatment of early ankylosing spondylitis, which is added to the existing options of tumor necrosis factor-alpha (TNF-α) inhibitors such as Humira and Remicade, is expected to increas
- Company
- One-shot Luxterna may soon receive reimbursement
- by Eo, Yun-Ho Dec 21, 2023 05:39am
- The one-shot retinal disease treatment 'Luxterna' is likely to be reimbursed soon. According to industry sources, Novartis Korea completed negotiations for Luxturna (voretigene neparvovec), a treatment for inherited retinal dystrophy (IRD), with the National Health Insurance Service on the 18th. Although the drug pricing negotiations d
- Opinion
- [Reporter’s view] Dilemma of compassionate use
- by Son, Hyung-Min Dec 20, 2023 05:41am
- Recently, certain global pharmaceutical companies have decided to discontinue compassionate use of its drugs, which permits patients access to investigational drugs, following the official approval of these drugs in Korea.. Consequently, patients without alternative treatment options are left with no choice but to obtain the drugs at a no
- Company
- Marketability of homegrown drugs being tested in the US
- by Chon, Seung-Hyun Dec 20, 2023 05:41am
- Domestic pharmaceutical and bio companies are entering the US one after another. GC Biopharma succeeded in entering the US market with its blood product on its third try. Since last year, 3 domestically developed drugs have passed the US market gateway, starting with Hanmi Pharmaceutical and Celltrion. Until now, homegrown drugs that have entere
- Policy
- Bill pending on substituting dispositions for illegal rebate
- by Lee, Jeong-Hwan Dec 20, 2023 05:40am
- A bill that would allow companies to substitute the price cut/rebate suspension dispositions made on their respective drugs due to rebates has been put on hold at the Standing Committee’s Legislation and Judiciary Subcommittee stage. The review for the bill continued after the Ministry of Health and Welfare, the ministry in charge of the
- Opinion
- [Reporter's view] Bothered by the PE exemption system
- by Eo, Yun-Ho Dec 20, 2023 05:40am
- The pharmacoeconomic evaluation exemption system is receiving much scrutiny. Under the pretense of improving the system, there are growing voices in favor of reducing of the system, supporting its reduced and limited application. These discussions reached culmination in a session titled, ‘On improving the pharmacoeconomic evaluation exem
